CAPVAXIVE 65 ug/.5mL

CAPVAXIVE 65 ug/0.5mL is a pneumococcal 21-valent conjugate vaccine designed for intramuscular administration. It is used to prevent pneumococcal infections caused by 21 serotypes. This vaccine is suitable for adults aged 18 and above.

CAPVAXIVE is a pneumococcal 21-valent conjugate vaccine primarily used to prevent infections caused by 21 serotypes of the Streptococcus pneumoniae bacteria. It is administered intramuscularly and is intended for adults aged 18 and above. This vaccine is designed to help the body build immunity against pneumococcal diseases, which can include conditions like pneumonia, bacteremia, and meningitis. The vaccine works by stimulating the immune system to produce antibodies against the specific serotypes of the bacteria.

After receiving CAPVAXIVE, some individuals may experience common effects such as pain, redness, or swelling at the injection site. Other possible effects include fatigue, headache, muscle pain, and mild fever. These effects are generally mild and temporary, resolving within a few days. Severe effects are rare but should be reported to a healthcare provider if they occur.

CAPVAXIVE should be administered by a healthcare professional. Individuals with a history of severe allergic reactions to any component of the vaccine should avoid it. It is important to inform the healthcare provider about any current illnesses or medications being taken. The vaccine should be stored and handled according to the manufacturer's guidelines to ensure its effectiveness.

CAPVAXIVE may interact with other medications or vaccines. It is important to inform the healthcare provider about all current medications, including over-the-counter drugs and supplements. The vaccine should not be administered with other vaccines without consulting a healthcare provider. Alcohol and certain medications may affect the immune response, so it is advisable to discuss any potential interactions with a healthcare professional.